Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis Pharmaceuticals |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00582738 |
This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant
Condition | Intervention | Phase |
---|---|---|
Recurrent Hepatitis C |
Drug: Everolimus Drug: standard treatment |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized, Controlled, Open Label, Two Arms, Exploratory Study to Evaluate the Effect of Everolimus on Histologically Assessed Fibrosis Progression (Ishak-Knodell) in Liver Transplant Recipients With Recurrent Hepatitis C Viral Infection as Compared to Standard Treatment. |
Estimated Enrollment: | 50 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | November 2009 |
Arms | Assigned Interventions |
---|---|
1: Experimental
everlimous
|
Drug: Everolimus
Hepatitis C recurrence after orthotopic liver transplantation (OLT)
|
2: Active Comparator
standard treatment
|
Drug: standard treatment
standard treatment
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply.
Contact: Novarts Pharmaceuticals | 41613241111 |
Argentina | |
Novartis Investigative site | Recruiting |
Buenos Aires, Argentina | |
Contact: Novartis 41613241111 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals ( External Affairs ) |
Study ID Numbers: | CRAD001H2301 |
Study First Received: | December 12, 2007 |
Last Updated: | December 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00582738 |
Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica |
Fibrosis progression recurrent hepatitis C viral infection |
liver transplant recipients everolimus Hepatitis C recurrence after orthotopic liver transplantation (OLT) |
Everolimus Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Chronic |
Fibrosis Disease Progression Hepatitis, Viral, Human Hepatitis C Recurrence |
Disease Attributes RNA Virus Infections Pathologic Processes Immunologic Factors Flaviviridae Infections |
Physiological Effects of Drugs Infection Immunosuppressive Agents Pharmacologic Actions |